| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | BAFF|CD257|TNFSF13B|BLYS|TALL1|THANK|TNFSF20|ZTNF4 |
| Assay Time | |
| Detection Method | |
| Detection Range | |
| Product Type | |
| Reactivity | |
| Sample Type(s) | Serum, Plasma, Cell Culture Supernatant, cell or tissue lysate, Other liquid samples |
| Sensitivity | |
| Species | |
| Storage | |
| Target | |
| UniProt # |
Background
human BAFF (B-Cell Activating Factor) high sensitivity is a molecular target commonly studied in biomedical research. Many proteins are studied as molecular readouts that can change with cellular state, tissue remodeling, or stress responses.
Biological role and mechanism
The biological role of BAFF (B-Cell Activating Factor) high sensitivity is typically understood in terms of its molecular category and interaction network. Depending on the model system, it may participate in cell–cell communication, intracellular signaling, enzymatic processing, or regulation of gene expression programs. Mechanistic interpretation is often strengthened by considering upstream regulators and downstream readouts rather than relying on a single marker.
Expression and abundance of BAFF (B-Cell Activating Factor) high sensitivity can vary by tissue, cell type, and physiological state. In many systems, levels are influenced by factors such as developmental stage, immune activation, metabolic status, and cellular stress. Because sample matrix and pre-analytical handling can affect measured concentrations, interpretation is typically strongest when experiments keep collection and processing consistent across groups.
Nomenclature and related terms
BAFF (B-Cell Activating Factor) high sensitivity may also be referenced as BAFF, CD257, and TNFSF13B in the literature or in databases. When comparing results across studies, confirm that the reported analyte refers to the same molecule, species context, and molecular form (e.g., precursor vs mature protein, or soluble vs membrane-associated forms).
Why it matters in research
- Understanding how BAFF (B-Cell Activating Factor) high sensitivity relates to signal transduction, tissue homeostasis, stress responses, and disease-model biology in biomedical research.
- Interpreting shifts in BAFF (B-Cell Activating Factor) high sensitivity levels alongside other pathway components or complementary markers.
- Connecting molecular changes to phenotypes such as inflammation, remodeling, metabolism shifts, or cell-state transitions (context-dependent).
Molecular forms and interpretation
For some targets, isoforms, proteolytic processing, or post-translational modifications (such as phosphorylation or glycosylation) can influence function and apparent abundance. If multiple molecular forms are expected in your model, align interpretation with the form most relevant to the biological question.
Disease and translational relevance
BAFF (B-Cell Activating Factor) high sensitivity has been investigated across diverse physiological and disease contexts, and changes in its abundance have been reported in areas aligned with biomedical studies. These associations are interpreted as research findings rather than diagnostic or therapeutic claims, and they should be evaluated alongside model-specific covariates and study design.
Can’t Find What You’re Looking For? We can help you source the best match or customize an ELISA solution for your study. Options may include alternative target synonyms, different species reactivity, sample type/matrix compatibility (serum/plasma/lysate/supernatant), assay format (sandwich/competitive), sensitivity/range, detection chemistry (colorimetric/fluorescent/chemiluminescent), plate format (pre-coated/uncoated, strips vs full plate), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
Increased soluble CD16b derived from activated neutrophils in plasma is associated with the pathogenesis and progression of IgA nephropathy
IF: 4.7 Journal: International Immunopharmacology Author: Department of Nephrology, Tianjin Medical University General Hospital, Tianjin, PR China. Cited Date: 2025-09-26
Early decrease of T-bet+ B cells during subcutaneous belimumab predicts response to therapy in systemic lupus erythematosus patients
IF: 3.3 Journal: Immunology Letters Author: Department of Translational and Precision Medicine, Sapienza University, Rome, Italy. Cited Date: 2024-12-13